SCIENTIFIC BACKGROUND

AIP, AKT1, ANKRD26, AP2S1, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1, CASR, CDC73, CDH1, CDH23, CDK12, CDK4, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CHEK1,

CHEK2, CTNNA1, DDB2, DDX41, DICER1, DLST, EGLN1, EPAS1, EPCAM, EPOR, ERCC2, ERCC3, ERCC4, ERCC5, ETV6, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FH, FLCN, GALNT12, GATA2, GCM2, GNA11, GNAS, GPR101, GREM1, HOXB13, KIF1B, KIT, KITLG, LZTR1, MAD2L2, MAX, MC1R, MEN1, MET, MITF, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PIK3CA, PMS1, PMS2, POLD1, POLE, POLH, POT1, PRKAR1A, PTCH1, PTCH2, PTEN, RAD50, RAD51B, RAD51C, RAD51D,

RAD54L, RB1, RECQL, RECQL4, RET, RFWD3, RNF43, RPS20, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SLC25A11, SLX4, SMAD4, SMARCA4, SMARCB1, SMARCE1, SPRED1, SRP72, STK11, SUFU, TERT, TMEM127, TP53,

TSC1, TSC2, UBE2T, VHL, WT1, XPA, XPC, XRCC2, XRCC3

 

The comprehensive cancer panel analyses 54 genes associated with >30 cancer types spanning across 10 organs and systems including breast, ovary, colon, endocrine system, pancreas, stomach, prostate, skin, kidney and nervous system/brain. The outcome of the test can be a risk estimation of developing cancer from a genetic cause. If a person has an estimated high cancer risk, certain actions can be taken to reduce the likelihood of developing the cancer such as undergoing routine monitoring. Additionally, family members can be informed and encouraged to have a test.

 

If a pathogenic variant is identified in one of the associated genes, the risk of developing one of these syndromes is higher as compared to the average risk in the general population. Conversely, if a pathogenic variant is not identified, this does not preclude the possibility of developing cancer from unknown genetic factors or sporadic causes.

 

Our genetic counsellors can provide a detailed interpretation of the diagnostic report and advice on preventative measures and surveillance recommendations.

 
Disorders included
 

  • Basal Cell Carcinoma Syndrome/Gorlin-Goltz Syndrome
  • Birt-Hogg-Dub Syndrome
  • Breast Cancer
  • Colorectal Cancer
  • Constitutional Mismatch Repair Deficiency
  • DICER1 Syndrome
  • Familial Adenomatous Polyposis
  • Fanconi Anemia
  • Gastric Cancer
  • Hereditary Mixed Polyposis
  • Hyperparathyroidism-Jaw Tumor Syndrome
  • Juvenile Polyposis Syndrome
  • Leiomyomatosis and Renal Cell Cancer
  • Li-Fraumeni Syndrome
  • Lynch Syndrome
  • Medullary Thyroid Carcinoma
  • Melanoma
  • Multiple Endocrine Neoplasia (MEN) 1
  • MEN2
  • MEN4
  • Neurofibromatosis, Type I
  • Ovarian Cancer
  • Pancreatic Cancer
  • Paragangliomas
  • Parathyroid Carcinoma
  • Peutz-Jeghers Syndrome
  • Pheochromocytoma
  • PTEN Hamartoma Tumor Syndrome
  • Renal Cell Carcinoma
  • Sessile Serrated Polyposis Cancer Syndrome
  • Tumor Predisposition Syndrome
  • Von Hippel-Lindau Syndrome

GENES

AIP, AKT1, ANKRD26, AP2S1, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1, CASR, CDC73, CDH1, CDH23, CDK12, CDK4, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CHEK1, CHEK2, CTNNA1, DDB2, DDX41, DICER1, DLST, EGLN1, EPAS1, EPCAM, EPOR, ERCC2, ERCC3, ERCC4, ERCC5, ETV6, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FH, FLCN, GALNT12, GATA2, GCM2, GNA11, GNAS, GPR101, GREM1, HOXB13, KIF1B, KIT, KITLG, LZTR1, MAD2L2, MAX, MC1R, MEN1, MET, MITF, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PIK3CA, PMS1, PMS2, POLD1, POLE, POLH, POT1, PRKAR1A, PTCH1, PTCH2, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54L, RB1, RECQL, RECQL4, RET, RFWD3, RNF43, RPS20, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SLC25A11, SLX4, SMAD4, SMARCA4, SMARCB1, SMARCE1, SPRED1, SRP72, STK11, SUFU, TERT, TMEM127, TP53, TSC1, TSC2, UBE2T, VHL, WT1, XPA, XPC, XRCC2, XRCC3

How to order

LATEST ARTICLES

A new meta-analysis links trans-kingdom gut microbiota (bacteria, eukaryotes, viruses, archaea) to immune checkpoint inhibitor (ICI) response in canc...

Read more

Reproductive health is a fundamental aspect of human well-being, affecting individuals and communities worldwide [1]. It encompasses a wide range of ...

Read more

It seems as though everyone is talking about artificial intelligence, usually referred to as AI, these days! Indeed, not only are AI tools now access...

Read more

Orphan drugs are those developed specifically for the treatment of rare diseases. Within the pharmaceutical industry, the drug development process is...

Read more

A study of 629 pregnancies with ultrasound-detected anomalies found that exome sequencing identified pathogenic variants in 14% of cases. The detecti...

Read more

Breast cancer is a type of cancer that originates in the breast cells. Genetic changes in the DNA of the healthy breast cells can lead to the formati...

Read more

Cardiovascular diseases affect the heart and blood vessels and are a leading cause of illness and death. Some are hereditary, and genetic testing can...

Read more

A recent study tracked molecular changes in 108 people over time, revealing that aging involves critical shifts around ages 44 and 60. These changes ...

Read more

In May 2024, the American Society of Clinical Oncology (ASCO) published new guidelines for germline genetic testing in patients with cancer (1). ...

Read more

Genetics as we know and understand it today has been shaped, over decades, by the work of many dedicated scientists around the world, and they all de...

Read more